OPEN ACCESS pISSN 2234-3806
eISSN 2234-3814

Table. 1.

Table. 1.

Patient demographics and baseline characteristics

Baseline characteristics Study population (N=287)
Age, median (IQR), yrs 49.0 (38.5–60.0)
Male sex, N (%) 149 (51.9)
Body mass index, median (IQR), kg/m2 23.0 (20.6–25.5)
Time since transplantation, median (IQR), yrs 5.6 (1.9–10.7)
Multiple kidney transplantations, N (%) 10 (3.5)
Original kidney disease, N (%)
Glomerulonephritis 90 (31.4)
Diabetes 38 (13.2)
ADPKD 21 (7.3)
Hypertension 9 (3.1)
Others 45 (15.7)
Unknown 84 (29.3)
Donor type, N (%)
Living donor 186 (64.8)
Deceased donor 101 (35.2)
Comorbidities, N (%)
Hypertension 166 (57.8)
Diabetes 77 (26.8)
Chronic liver disease 9 (3.1)
Chronic pulmonary disease 1 (0.3)
Immunosuppressive regimen, N (%)
CNI+antimetabolite+steroid 216 (75.3)
CNI+steroid 34 (11.8)
CNI+antimetabolite 15 (5.2)
CNI+mTORi+antimetabolite+steroid 6 (2.1)
mTORi+antimetabolite+steroid 3 (1.0)
Other regimens 13 (4.4)
Laboratory values, median (IQR) or mean±SD
WBCs, ×109/L 7.0 (5.8–8.4)
Hb, g/dL 13.4±1.8
ANC, /µL 3,994 (3,154–5,216)
MDRD eGFR, mL/min/1.73 m2 59.7±18.2
Tacrolimus trough level, ng/mL* 5.7 (4.6–6.7)
Type of previous COVID-19 vaccination (first/second), N (%)
ChAdOX1-S/ChAdOX1-S 61 (21.2)
BNT162b2/BNT162b2 126 (43.9)
mRNA-1273/mRNA-1273 17 (5.9)
ChAdOX1-S/BNT162b2 83 (28.9)

*Tacrolimus trough levels were available for 274 patients on tacrolimus.

Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; ANC, absolute neutrophil count; CNI, calcineurin inhibitor; COVID-19, coronavirus disease; eGFR, estimated glomerular filtration rate; IQR, interquartile range; MDRD, modification of diet in renal disease; mTORi, mammalian target of rapamycin inhibitor; WBCs, white blood cells; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

© Ann Lab Med